Franck Amblard

USPTO Granted Patents = 15 (Patent Applications = 10)

CIPO Patents = 2 (Patent Applications = 16)

EPO Patents = 2 (Patent Applications = 18)

Average Co-Inventor Count = 5.1

ph-index = 4

Forward Citations = 71(Granted Patents)

Location History:

Decatur, GA (US) (2018)
Tucker, GA (US) (2014 - 2020)
Atlanta, GA (US) (2018 - 2024)

Company Filing History:

Cocrystal Pharma, Inc.

where one patent can have more than one assignee

Years Active: 2014-2025

Loading Chart...

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12318393 - Modulators of orphan nuclear receptors for NASH and other metabolic disorders (2025-06-03),

2. 12268723 - Peptidomimetics for the treatment of coronavirus and picorna virus infections (2025-04-08),

3. 12239655 - Combined modalities for nucleosides and/or NADPH oxidase (NOX) inhibitors as myeloid-specific antiviral agents (2025-03-04),

4. 11963972 - Antiviral agents and nucleoside analogs for treatment of Zika virus (2024-04-23),

5. 11859014 - Peptidomimetics for the treatment of Norovirus infection (2024-01-02),

6. 11629125 - Elimination of hepatitis b virus with antiviral agents (2023-04-18),

7. 11207370 - Peptidomimetics for the treatment of coronavirus and picornavirus infections (2021-12-28),

8. 11021513 - Peptidomimetics for the treatment of norovirus infection (2021-06-01),

9. 10752584 - Elimination of hepatitis B virus with antiviral agents (2020-08-25),

10. 10011629 - Nucleoside analogs for treatment of the flaviviridae family of viruses and cancer (2018-07-03),

11. 9932326 - Potent and selective inhibitors of hepatitis C virus (2018-04-03),

12. 9926295 - Potent and selective inhibitors of hepatitis C virus (2018-03-27),

13. 9809616 - Pyrimidine nucleosides and their monophosphate prodrugs for the treatment of viral infections and cancer (2017-11-07),

14. 9181227 - Potent and selective inhibitors of hepatitis C virus (2015-11-10),

15. 8859595 - Potent and selective inhibitors of hepatitis C virus (2014-10-14),

Title: **Franck Amblard: Innovator in Antiviral Treatments**

Introduction

Franck Amblard, based in Tucker, Georgia, is a prolific inventor with a remarkable portfolio that includes 14 patents. His work has significantly contributed to the field of antiviral treatments, addressing some of the most pressing viral infections affecting humans today.

Latest Patents

Amblard's latest patents focus on groundbreaking compounds and compositions designed for the prevention and treatment of coronavirus and picornavirus infections. One notable invention outlines methods for potentially treating infections caused by severe acute respiratory syndrome viruses, including human coronavirus 229E, SARS, MERS, SARS-CoV-1 (OC43), and SARS-CoV-2. Additionally, he has developed compounds aimed at treating patients co-infected with multiple viruses, including norovirus. Another significant patent involves nucleoside compounds that target HIV and other viral infections specifically in myeloid cells, aiming to effectively eliminate infections in patients affected by these viruses.

Career Highlights

Throughout his career, Franck Amblard has made impactful contributions while working at prestigious institutions such as Emory University and Cocrystal Pharma, Inc. His research and innovations have earned him recognition as a leader in virology and antiviral drug development.

Collaborations

Amblard has collaborated with esteemed professionals in his field, including Steven J. Coats. These collaborations have resulted in advancements that enhance the understanding and treatment options available for viral infections.

Conclusion

Franck Amblard’s innovative spirit and dedication to combating viral infections have paved the way for new therapeutic options. His ongoing research continues to inspire change in the medical community, offering hope to those affected by viral diseases. As the world faces evolving challenges from various viruses, the significance of his work remains paramount.

This text is generated by artificial intelligence and may not be accurate.